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classifying Her2-neu positive gastric adenocarcinoma
Ayesha Ahmed and Dalal M. Al-Tamimi
Department of Pathology, College of Medicine, King Fahd Hospital of Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
ABSTRACT
Her2-neu overexpression has a pathogenetic, therapeutic and a controversial prognostic role in
gastric cancer. p-53mutation status andKi-67proliferation index are establishedprognosticmarkers
in many tumors. In this study we evaluated p-53 and Ki-67 in relation to Her2-neu positive and
negative gastric adenocarcinoma (GA). This cross-sectional study was carried out at King Fahd
Hospital of ImamAbdulrahmanbinFaisal University. Fifty cases ofGAwere retrieved frompathology
archives. Clinico-pathological parameters were evaluated. Immunohistochemical protein analysis
for Her2-neu, Ki-67 and p-53 was carried out. Fluorescent in situ hybridization (FISH) analysis was
done for Her2-neu positive cases showing 2+ immunoexpression. Frequency of Ki-67 and p-53
positivity in Her2-neu positive cases was calculated and compared with those in Her2-neu negative
cases. Correlation of clinicopatological parameters with Her2 positive and negative cases, p-53
mutation status and Ki-67 proliferation indexwas carried out. Her2-neu overexpressionwas present
in 12% (n = 6) cases. A high Ki-67 was seen predominantly in Her2-neu positive cases (83%, n = 5).
Her2-neu negative cases (n = 44) showed moderate (31.88%, n = 14) to low (34%, n = 15) Ki-67.
Diffuse p-53 positivitywas seenpredominantly inHer2-neupositive cases (33.33%, n=2). Focal p-53
was seen mainly in Her2-neu negative cases 56.8% (n = 25). Negative p-53 was seen to be
independent of Her2-neu status. Her2-neu positivity is strongly associated with diffuse p-53 muta-
tion status and high Ki-67 proliferation. Her 2-neu negative status is associated with focal p-53
positivity and low to moderate Ki-67 proliferation index. Such stratifications in prognostic markers
could not only be predictive in patient’s prognostics but could also form a basis of molecular
classification of gastric cancer.
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1. Introduction
Gastric cancer is one of the most common and aggres-
sive malignant tumors worldwide with a high mortality
rate, preceded only by lung cancer [1]. Globally gastric
cancer is the fourth most common cancer and second
leading cause of cancer related mortality with a 5-year
overall survival rate less than 25% [2].
Her2-neu overexpression has a pathogenetic, ther-
apeutic and prognostic role in gastric cancer.
Evaluation of Her2-neu overexpression for targeted
therapies is currently the mainstay treatment strategy
[3]. Her2-neu as a negative prognostic parameter has
established a strong foot holds in breast cancer. The
ToGA trial (Trastuzumab for Gastric Cancer) attributed
a similar status to Her2-neu in gastric cancer, yet no
unanimous consensus has evolved so far in this
regards till now [4,5]. Prognostic factors defined for
the staging and therapeutic interventions in gastric
cancer are imprecise as patients with similar para-
meters actually prove to be at different levels clini-
cally, attributing a controversial prognostic status to
Her2-neu overexpressivity [6].
Ki-67 and p-53 are established prognostic markers
in many tumors. Ki-67 is a useful predictive and prog-
nostic marker in cancers with a proliferation index
exceeding 10%-14% delineating a high-risk prognos-
tic category [7]. A pre-chemotherapy evaluation of
rate of Ki-67 is also a strong predictor of efficacy of
the therapy [8]. p-53 is the most commonly mutated
gene in human cancer with a critical role in cell cycle
regulation and tumor suppression. In gastric lesions,
an increasing frequency of p-53 mutations is seen in
H.pylori infection, a key player in gastric carcinogen-
esis, intestinal metaplasia, gastric dysplasia and gastric
carcinoma [9]. Its expression is associated with
advanced staged gastric carcinomas with a poorer
postoperative prognosis.
In this study p-53 and Ki-67 were assessed in
Her2-neu positive and negative gastric adenocarci-
noma (GA) with an idea to find an association
between Her2-neu status and these prognostic mar-
kers that could segregate a subset of more aggres-
sive GA, requiring a tailored, separate and
aggressive therapeutic approach.
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2. Material and methods
This cross sectional study was carried out at Pathology
Department of King Fahd Hospital of Imam
Abdulrahman bin Faisal University in 2015–2016.
Approval of the protocol was granted by the
Institutional Review Board.
A sample size of 45 (one sample implies a biopsy
specimen from an individual patient) from was calcu-
lated for a study population (registered patients) of
10,000, using a confidence level of 95%, margin of
error of 5% and response rate of 3%, based on cancer
incidence report for gastric cancer of Saudi Arabia-
2010 [10]. This sample was drawn from pathology
archives of the department, and comprised gastric
carcinoma resection specimens and endoscopic biop-
sies over a period of 10 years preceding the study.
The inclusion criteria were availability of complete
patient record, representative paraffin blocks, and suf-
ficient tissue material to perform the required histo-
patholgical procedures. A total of 55 cases were
selected initially on the assumption that some cases
might not qualify on selection criteria at the time of
tissue processing and staining. However we suc-
ceeded to get 50 qualifying samples, therefore we
reported out of 50 instead of 45.
GA were histologically classified according to Laurens
[11] which divides GA into two types; intestinal (consist-
ing of well-formed tubules) and diffuse (diffuse tumor
infiltration without well-formed tubules, frequently with
signet ring cells).
Immunohistochemical staining using the labeled
streptavidin-biotin method with 3,3ʹ-diaminobenzidine
as a chromagen was performed for Her2-neu, p-53 and
Ki-67 on 4 µm thick paraffin sections cut from conven-
tional blocks. Prediluted antibodies were used. Her-2
neu(clone CB11), Ki-67(clone MIB-1)) and p-53(clone
DO-7) were obtained from Ventanna, Dako and
Navacastro respectively. The staining was performed
concurrently in a Ventana Benchmark automated immu-
nostainer according to the manufacturer’s instructions
(Ventana Medical Systems Inc., Strasbourg, France). The
immunostained sections were examined under a light
microscope and evaluated manually by both the
authors. Any interpretational discrepancies were
resolved under a double-headed microscope.
A modified scoring system for GA that has been
shown to be predictive in a large Phase III ToGA trial
was used for Her2-neu expression in gastric cancer [12].
The 10% cut-off rule was kept in resection specimen,
whereas in biopsies any group of at least five tumor cells
showing distinct membranous staining (typically lateral
at cell-cell junctions) was considered specific. The
MicroscopeMagnification rulewas applied to determine
Her2-neu expression.
Demonstration of distinct intercellular membranous
staining whether linear, basolateral or ring-shaped was
required. If a strong intensity could be seen at 2.5×–5×
magnification it was designated a score of 3 + . A visible
weak to moderate staining at 10×–20× was scored as 2
+, barely visible staining at 20×–40× was scored as 1+
and a negative stainingwas given a score of 0. A score of
2+ and 3+ was considered as Her2-neu positive (over-
expression). While the scores of 0 and 1+ were regarded
as Her2-neu negative [12]. The unequivocal cases (Her2-
neu 2+) were confirmed by FISH analysis.
FISH for HER2 gene amplification was conducted on
FFPE of gastric tumor according to the protocol of FDA
approved kit from Abbott. The probes consist of a dual
color, two probe mixture of DNA sequences on specific
regions of chromosome 17, including the centromere of
chromosome 17 (CEP17) and the Her2 gene region at
chromosome 17q12. Signals were visualized under a
Zeiss Axioskop microscope (Zeiss, Germany) using a
FITC/Rhodamine dual band filter. We followed the
ASCO criteria for analyzing the results. The guidelines
stated that Her2/CEP17 ratio <2 is considered a normal
result, ≥2 is considered an amplified abnormal result.
Ki-67 and p-53 were done for both Her2-neu positive
and negative cases. Frequency of Ki-67 and p-53 were
compared between Her2-neu positive and negative
cases and statistical significance was determined.
Ki-67 expression was defined as the presence of
nuclear staining. The percentage of cells expressing
Ki-67 was determined by counting 1000 cells/slide. The
percentage of positive cells was scored as follows: less
than 10% = low proliferative activity, 10%–40% =moder-
ate proliferative activity and more than 40% = high pro-
liferative activity [13].
p-53 mutation status was defined as positive in
presence of nuclear staining. Cytoplasmic staining
was considered negative. Tumors were considered
focally positive when unequivocal staining was pre-
sent in 10%–50% of tumor cells and as diffusely posi-
tive when more than 50% of the tumor cells were
positive [9].
Data was entered into SPSS (version 19). Descriptive
statistics were used to calculate frequencies (percen-
tages) for expression of Her2-neu, Ki-67 proliferation
index and p-53mutation status. Frequency of Ki-67 and
p-53 positivity was compared between Her-2neu posi-
tive and negative cases using Chi square test. A P value
of less than 0.05 was considered as statistically
significant.
3. Results
Out of a total of 50 cases of gastric cancer retrieved, 43
specimens were biopsies and 7 were partial gastrec-
tomies. Male to female ratio was 37:13 and median
age of the patients was 67 years (maximum &minimum
88 & 42 years). Diffuse type gastric cancer was seen in 23
(46%) and intestinal type in 27 (54%) of cases. The
clinicopathological parameters are presented in
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Table 1. The relationship of Ki-67 proliferation index and
p-53 mutation status with clinico-pathological para-
meters is presented in Tables 2 and 3.
Her2-neu expression pattern is given in Table 4
while Ki-67 proliferation index and p-53 mutation
status is given in Table 5 respectively. In Her2-neu
positive and negative cases, p-53 mutation status
and Ki-67 proliferation index are represented in
Tables 6 and 7 respectively.
Her2-neu positivity was found in six cases (Table 4).
Diffuse p-53 positivity was seen in 33.33% (n = 2) of
Her2-neu positive cases as compared to 15.91% (n = 7)
in Her2-neu negative cases. (Diffuse p-53 was signifi-
cantly high, P value ˂0.01 in Her2-neu positive cases)
(Table 6).
Focal p-53 positivity was seen in 33.33% (n = 2) of
Her2-neu positive cases as compared to 56.8%
(n = 25) in Her2-neu negative cases. (Focal p-53 was
significantly high, P value ˂0.01 in Her2-neu negative
cases). (Table 6)
Negative p-53 was observed to be independent of
Her2-neu status.
A high Ki-67 was seen in 83% (n = 5) of Her2-neu
positive cases as compared to 34% (n = 15) in Her2-neu
negative cases. (High Ki-67 was significantly high, P
value ˂0.01 in Her2-neu positive cases). (Table 7)
A moderate Ki-67 was seen in 16.66% (n = 1) of
Her2-neu positive cases as compared 31.88% (n = 14)
in Her2-neu negative cases. (Moderate Ki-67 was sig-
nificantly high P value ˂0.01, in Her2 neu negative
cases). (Table 7)
A low Ki-67 was seen in 0% (n = 0) of Her2-neu
positive cases as compared 34% (n = 15) in Her2-neu
negative cases. (Low Ki-67 is significantly high P value
˂0.01, in Her2 neu negative cases). (Table 7)
4. Discussion
Gastric cancer is not one disease entity but a complex
combination of multiple genetic and epigenetic
alterations. Marked variation in the prognosis of
patients with GA within a similar pathological stage
requires the identification of subgroups of patients
with a more aggressive disease.
In this study an overall estimation of Her2-neu
overexpression, p-53 mutation status and Ki-67 pro-
liferation index in GA along with evaluation of p-53
and Ki-67 in Her2-neu positive and Her2-neu negative
GA was evaluated.
Overall in this study there was a cumulative 12% of
Her-2neu over expressivity with 8% showing 2+ and
4% demonstrating 3+ immunoreactivity (Figure 1(a,b)).
Her2-neu over expression in GA has been reported to
range from 11.7% [14] to 23% [15] in different studies.
Only some studies have documented Her2-neu protein
overexpression or gene amplification to be associated
Table 1. Cliniopathological parameters in Her2-neu positive and negative gastric adenocarcinoma (n = 50).





Her 2 neu status > 39 40–50 <50 M F Proximal Distal Diffuse Intestinal Low (Well – Mod) High (Poor +ve -ve +ve -ve
Positive - 6 - 6 5 1 - 6 5-Mod 1 4 2 3 3
% age (n = 6) 0 100 0 100 0 83 17 0 100 83 17 67 33 50 50
Negative - 16 28 29 15 20 24 23 21 15 29 18 26 16 28
% age (n = 44) 0 36 64 66 34 45 55 52 48 34 66 41 59 36 64
Table 2. Relationship between Ki-67 proliferation index in












(Poor) +ve -ve +ve -ve
Mod to high n = 35 5 30 21 14 17 18
% age −100 14 86 60 40 49 51
Low n = 15 15 0 1 14 2 13
% age 100 100 0 7 93 14 86
Table 3. Relationship between p-53 mutation status in gas-












(Poor) +ve -ve +ve -ve
Focal n = 27 15 12 9 18 8 19
% age −100 56 44 33 67 30 70
Diffuse n = 9 2 7 8 1 7 2
% age 100 22 78 89 11 78 22
Negative n = 14 3 11 5 9 4 10
% age 100 21 79 36 64 29 71
Table 4. Her2-neu expression in gastric adenocarcinoma
(n = 50).
Her-2 neu status Her-2 neu staining intensity N % age
Negative 0 43 86*
1+ 1 2
Positive 2+ 4 8
3+ 2 4
Her2-neu 1+ (negative)2+ (moderately positive)3+ (strongly positive)
*P ˂0.001 by chi square test.
Table 5. Ki-67 proliferation index p-53 mutation status and in
gastric adenocarcinoma (n = 50).
Ki-67 p-53
High Mod Low Focal Diffuse Negative
N 20 15 15 27 9 14
%age 40 30 30 54 18 28
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Table 6. Crosstab showing distribution of p-53 mutation status according to Her2-neu status of gastric




Positive (n = 6) Total (n = 6) 2 (33.33%)* 2 (33.33%) 2 (33.33%)
2+ (n = 4) 1 1 2
3+ (n = 2) 1 1 0
Negative (n = 44) Total (n = 44) 7 (15.91%) 25 (56.81%)* 12 (27.27%)
+1 (n = 1) 0 1 0
0 (n = 43) 7 24 12
*: P-value <0.01 on chi square test.
Table 7. Crosstab showing distribution of Ki-67 expression according to Her2-neu status of gastric




Positive (n = 6) Total (n = 6) 5 (83%)* 1 (16.66%) 0 (0%)
2+ (n = 4) 3 1 0
3+ (n = 2) 2 0 0
Negative (n = 44) Total (n = 44) 15 (34%) 14 (31.81%)* 15 (34%)*
+1 (n = 1) 1 0 0
0 (n = 43) 14 14 15




Figure 1. Her 2 neu ‘3+’ immunoreactivity with its associated high Ki-67 proliferation index and diffuse p-53 mutation status.
(a) Her2 neu3+ (×20); (b) Her2 neu3+ (×40); (c) High Ki-67 (×20); (d) High Ki-67 (×40); (e) Diffuse p-53 (×20); (f) Diffuse p-53 (×40).
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with a worse prognosis [16] however larger studies
could not confirm this as an independent prognostic
factor [17,18]. Her2-neu prognostic significance is
further minimized by its reported loss in approximately
one third of patients when treated with trastuzumab,
leading to drug resistance. Additionally with advanced
aggressive Her2-neu positive tumors, other genetic
alterations involving specifically p-53 (92%) and other
cell-cycle mediators supervene [19]. These data sug-
gest the need for periodic Her2-neu status evaluation
during therapy but also incorporation and monitoring
of other cell cycle regulators such as p-53 from the start
so as to have a baseline level available for further
patient evaluation.
In gastric carcinomas, p-53 expression frequency has
been reported to vary from 46% [20] to 61% [21].In our
set of cases, with a total of 72% of cases revealing focal
to diffuse p-53 expression (Figure 1(e,f)), a somewhat
higher representation is seen. Out of this Her2-neu posi-
tive cases predominantly showed diffuse p-53 positivity
(33.33%) while Her2-neu negative cases (56.81%)
revealed mostly focal p-53 positivity. Negative p-53
expression was seen irrespective of Her2-neu status.
This stratification of p-53 and Her2-neu expression pat-
tern has not been reported before. p-53 mutation is the
most common genetic alterations in human cancer
initiation and progression and has been reported to be
an independent prognostic factor in patient’s overall
and disease-free survival in gastric cancer [22]. A strati-
fied expression was seen in our cases with increase from
focal in Her2-neu negative to diffuse in Her2-neu posi-
tive cases. Could this point out toward a direct genetic
link between these two entities with both increasing
concomitantly and being codependent and not inde-
pendent factors?
Therapeutically this link could be important as cur-
rently anti-p53 therapies [23] are in stages of devel-
opment. Addition of these to anti-Her2-neu drugs
such as traztuzumab might improve patients’ clinical
outcome that has been so poor till now.
Based on the above discussion Her2-neu and p-53
cases can be categorized into two groups. One set of
Her2-neu positive cases that retain p-53 expression
but lose their Her2-neu co- expression and when
cancer becomes advanced. This set will be the ones
that will be facing traztuzumab resistance. Addition of
anti-p53 might be helpful to some extent. The other
set can be the ones that have conjoined expression of
Her2-neu and diffuse p-53. A double therapy target-
ing both could be beneficial to these patients. More
extensive studies unravelling these facts at genetic
and clinical levels need to be carried out.
In our study an overall high to moderate Ki-67 prolif-
erating index was seen in 70% of cases. A range of 70%–
76% has been reported in other studies [24,25]. Ki-67 is a
nuclear protein that is expressed in proliferating cells
throughout the cell cycle. In a meta-analysis comprising
a total of 5600 gastric cancer patients from 29 studies, it
was concluded that a high Ki-67 expression could serve
as a predictive biomarker for poor prognosis in gastric
cancer patients [26]. The value of Ki-67 becomes more
marked if it is seen in conjunction with Her2-neu positiv-
ity. An association between Her2-neu overexpression, Ki-
67 proliferation index and a high grade and stage has
been reported [27]. In our study 83% of Her2-neu positive
cases showed a high Ki-67 proliferation index (Figure 1(b,
c)). Her-2 neu negative cases revealed mainly moderate
to low Ki-67. Hence Ki-67 expression increases with Her2-
neu overexpression. Could it be that the concept of Her2-
neu gene working as an independent prognostic marker
needs to be reevaluated? At the genetic level Her2-neu
and Ki-67maybe partners that express collectively in high
grade advanced gastric carcinomas. The protein expres-
sion of Ki-67 and Her-2neu has overlapping features in
the clinical pathologic characteristics of gastric cancer. Ki-
67 is strongly linked to gastric cancer differentiation,
infiltration and lymphatic spread, whereas Her-2 neu
plays a role at the level of tumor differentiation and
nodal metastasis [28]. Stratification of cases by Her2-neu
status and extent of Ki-67 expression could be a very
useful tool for selection of specific therapies as Ki-67 as
a molecular target for anticarcinogenic therapies is being
explored [29].
A more advanced gastric cancer genetic profiling
needs to be determined with formulation of molecular
classification of gastric cancer as is currently being done
in breast cancer. This will pave the way for individualized
targeted treatment options based on gastric cancer
molecular characteristics that could improve the patient’s
prognostics that have been so dismal till now.
5. Conclusion
Her2-neu positivity is strongly associated with diffuse
p-53 mutation status and high Ki-67 proliferation. Her
2-neu negative status is associated with focal p-53
positivity and low to moderate Ki-67 proliferation
index. This strong association in Her2-neu positive
cases could be the basis of a separate molecular subset
of gastric carcinoma, a potential candidate for separate
tailored molecular therapeutic regimens.
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